Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series A financing rounds, raising USD 40 million in total. Lilly Asia Ventures led the angel funding, while Zhejiang United Investment/Zhejiang Silk Road Fund led the Series A, with contributions from Junson Capital, another “industrial group,” and Lilly Asia Ventures. Proceeds will go towards continuous research and development (R&D) and manufacturing of the company’s whole product pipeline.
Company Background and Facilities
Founded in 2019, Lavamed boasts office space, production plants, 10,000-class clean workshops, and world-leading production line equipment covering 8,500 square meters.-Fineline Info & Tech
